Since we recently showed [29] that a bispecific antibody (bsAb) directed to TRAIL-R2 as TAA and to CD3 as triggering molecule, can efficiently redirect CD3+ T lymphocytes cytotoxicity toward cancer cells (Fig. 7a), we explored if the increase of TRAIL-R2 following siCHKA could also result in an improvement of the bsAb-mediated T cell anticancer activity. Here, TNFRSF10B is linked to cancer.